Anavex Life Sciences Corp (AVXL)

[OFP]

“Genomic signature found and to be reported at an upcoming conference. The signature allows them to accurately predict who will benefit most from 2-73. This way the data can be used in all future trials.”

This is quite a dramatic statement - do we interpret this statement that patients with these signature will benefit from A2-73 such that it will have positive impact on Alz?

If they PR it officially - it will be big news and lot of questions as to veracity of this claim

I think you've hit on the problem of "questions of veracity". They can PR all they want. It is unknowable, patently absurd, and is just fodder for the ignorant.